Gilder Gagnon Howe & Co. LLC Buys New Position in Accelerate Diagnostics, Inc. (AXDX)

Gilder Gagnon Howe & Co. LLC bought a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 39,641 shares of the medical research company’s stock, valued at approximately $890,000. Gilder Gagnon Howe & Co. LLC owned 0.07% of Accelerate Diagnostics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AXDX. Legal & General Group Plc lifted its stake in shares of Accelerate Diagnostics by 0.3% in the 1st quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 15 shares during the period. CLS Investments LLC purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at approximately $137,000. Quantbot Technologies LP purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at approximately $228,000. UBS Asset Management Americas Inc. purchased a new position in shares of Accelerate Diagnostics in the 2nd quarter valued at approximately $243,000. Finally, SG Americas Securities LLC lifted its stake in shares of Accelerate Diagnostics by 87.8% in the 2nd quarter. SG Americas Securities LLC now owns 11,054 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 5,169 shares during the period. Institutional investors own 44.44% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gilder Gagnon Howe & Co. LLC Buys New Position in Accelerate Diagnostics, Inc. (AXDX)” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2017/11/16/gilder-gagnon-howe-co-llc-buys-new-position-in-accelerate-diagnostics-inc-axdx.html.

Accelerate Diagnostics, Inc. (AXDX) opened at $20.75 on Thursday. Accelerate Diagnostics, Inc. has a one year low of $16.75 and a one year high of $30.45.

A number of research analysts have recently commented on the company. ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating and two have given a buy rating to the stock. Accelerate Diagnostics presently has a consensus rating of “Hold” and a consensus price target of $33.00.

In related news, Director Jack W. Schuler acquired 20,000 shares of the stock in a transaction on Monday, November 13th. The stock was acquired at an average price of $18.98 per share, for a total transaction of $379,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack W. Schuler acquired 51,600 shares of the stock in a transaction on Wednesday, October 11th. The shares were bought at an average price of $20.27 per share, with a total value of $1,045,932.00. The disclosure for this purchase can be found here. Insiders have acquired 1,006,167 shares of company stock valued at $19,431,424 in the last quarter. 50.00% of the stock is owned by company insiders.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply